The antibody could greatly improve our ability to defend against future variants.
By BOSTON CHILDREN'S HOSPITAL
Therapeutic antibodies that were effective early in the pandemic have lost their efficacy as SARS-CoV-2 has changed and mutated, and more recent variants, particularly Omicron, have learned how to circumvent the antibodies our systems produce in response to vaccinations.
We may be able to better guard against possible variations thanks
to a new, widely neutralizing antibody created at Boston Children’s Hospital. In tests, it
neutralized all known SARS-CoV-2 variants of concern, including all Omicron
variants.
“We hope that this humanized antibody will prove to be as
effective at neutralizing SARS-CoV-2 in patients as it has proven to be thus
far in preclinical evaluations,” says Frederick Alt, Ph.D., of the Program in
Cellular and Molecular Medicine at Boston Children’s Hospital, who co-led the
research.
In a study that was published in Science Immunology, Alt and Sai Luo, Ph.D., utilized a modified version of a humanized mouse model that his lab had previously used to look for broadly neutralizing antibodies to HIV, another virus that often mutates.
Since the mice effectively have built-in human immune systems, the
model closely resembles how the trial-and-error process our immune system uses
to create increasingly effective antibodies.
The researchers initially introduced two human gene segments into the mice, causing their B cells to create a wide repertoire of humanized antibodies in a short period of time. They subsequently exposed the mice to the original Wuhan-Hu-1 strain of the virus’s SARS-CoV-2 spike protein, which is the main protein targeted by our antibodies and current vaccines. The modified mice developed nine lineages, or “families,” of humanized antibodies that bonded to the spike in response.
Together with a Duke University team led by Dr. Barton Haynes,
Alt and Luo then assessed the efficacy of these antibodies. Antibodies from
three of the nine lineages were effective in neutralizing the original
Wuhan-Hu-1 virus. The SP1-77 antibody and other members of its lineage, in particular,
demonstrated extremely wide activity, neutralizing Alpha, Beta, Gamma, Delta,
and all prior and current Omicron strains.
A new approach to virus
neutralization
What caused the SP1-77 antibody to be so broadly
neutralizing? Structural studies by a collaborating team led by Bing Chen,
Ph.D. and Jun Zhang, Ph.D. at Boston Children’s Hospital and the Haynes group
at Duke, showed that SP1-77 works differently from current antibodies (either
therapeutic antibodies or those we make in response to current vaccines).
Many of the existing antibodies work by attaching to the
receptor-binding domain (RBD) of the spike in certain regions, preventing
SARS-CoV-2 from binding to our cells’ ACE2 receptors, which is the initial
step in infection. The SP1-77 antibody binds to the RBD as well, but in a
completely different manner that does not prevent the virus from binding to
ACE2 receptors.
Using a novel live-cell imaging platform described in a
preprint, collaborators Alex Kreutzberger, Ph.D. and Tomas Kirchhausen, Ph.D.,
of Boston Children’s Hospital showed that SP1-77 prevents the virus from fusing
its outer membrane with the membrane of the target cell. This thwarts the final
necessary step that throws the door open to infection.
These features may inform the design of new SARS-CoV-2
vaccines. “SP1-77 binds the spike protein at a site that so far has not been
mutated in any SARS-CoV-2 variant, broadly neutralizing current variants by a
novel mechanism,” says Kirchhausen.
Reference: “An Antibody from Single Human VH-rearranging
Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane
Fusion” by Sai Luo, Jun Zhang, Alex J.B. Kreutzberger, Amanda Eaton, Robert J. Edwards,
Changbin Jing, Hai-Qiang Dai, Gregory D. Sempowski, Kenneth Cronin, Robert
Parks, Adam Yongxin Ye, Katayoun Mansouri, Maggie Barr, Novalia Pishesha, Aimee
Chapdelaine Williams, Lucas Vieira Francisco, Anand Saminathan, Hanqin Peng,
Himanshu Batra, Lorenza Bellusci, Surender Khurana, S. Munir Alam, David C.
Montefiori, Kevin O. Saunders, Ming Tian, Hidde Ploegh, Tom Kirchhausen, Bing
Chen, Barton F. Haynes and Frederick W. Alt, 11 August 2022, Science Immunology.
DOI: 10.1126/sciimmunol.add5446
The study was funded by the Howard Hughes Medical Institute,
the Bill & Melinda Gates Foundation, the NIH NIAID Consortia for HIV/AIDS
Vaccine Development, the Massachusetts Consortium on Pathogen Readiness,
Emergent Ventures, the Food and Drug Administration, the NIH Maximizing
Investigators’ Research Award, NIH Grant AI163019, the Danish Technical
University and SANA, IONIS, and a Harvard Virology Program NIH training grant.